key: cord-0761429-s4v2g0e0 authors: Soto-Perez-de-Celis, Enrique; Arrieta, Oscar; Bargalló-Rocha, Enrique; Campos-Gómez, Saúl; Chavarri-Guerra, Yanin; Chávez-Nogueda, Jessica; González-Lara, Fernanda; Pérez-Jacobo, Fernando; Martínez-Said, Héctor title: COVID-19 vaccine guidance for patients with cancer in Mexico: report from the working group of the Mexican Society of Oncology date: 2021-07-30 journal: Arch Med Res DOI: 10.1016/j.arcmed.2021.07.005 sha: 1d31f92d9f4b72546eabac4192dc83f4839cd121 doc_id: 761429 cord_uid: s4v2g0e0 nan  Adults currently living with active cancer and undergoing antineoplastic treatment or who are planning to initiate treatment, especially for hematological neoplasms, should be priority for vaccine rollout, particularly considering limited vaccine availability.  Among adults with cancer who receive two-dose vaccines, it is imperative that the administration of the second dose not be delayed under any circumstance.  Adults with cancer from rural and marginalized areas should be considered a priority in vaccine rollout strategies.  Social distancing and mask wearing strategies are highly encouraged even after vaccination for adults with cancer.  We recommend strengthening national cancer registries in order to facilitate the timely identification of patients at a higher risk for worse outcomes in the event of future pandemics. Although COVID-19 affects a wide variety of individuals, several factors increase the risk for severe COVID-19 presentation and mortality, including advanced age, obesity, diabetes, cardiovascular illness, and immunosuppression (3). Cancer is a frequently recognized comorbidity, and patients diagnosed with cancer have an increased risk of death from COVID-19 (RR 1.8) (4), particularly patients with hematological malignancies (RR 2.5), and patients with a recent diagnosis (5, 6) . Patients with cancer have diverse immune alterations, affecting both innate and adaptive immune responses. As such, patients might be immunocompromised as a direct consequence of the neoplastic process, or as an effect of anti-tumor treatment, including the use of immune checkpoint inhibitors and supportive medication such as steroids. Furthermore, patients with cancer are often diagnosed at an advanced age and in the context of other comorbidities which might also drive poor COVID-19 outcomes, including smoking, metabolic comorbidities, and poor functional status (5) . They also more frequently attend hospital settings and are in contact with healthcare providers in closed spaces. Additionally, several sociodemographic factors have been associated with worse COVID-19 outcomes in Mexico, including living in socially deprived areas andhigh-density urban dwellings (7). Social distancing measures have reduced COVID-19 spread, though they have been insufficient to stop the pandemic (8, 9) . inflammation can be observed, symptoms mostly self-limit in 3-5 d following vaccination, there have been no additional safety signals or serious adverse events among adults with cancer which could justify differing or limiting vaccine rollout to this patient subgroup, and COVID-19 vaccines appear to be both effective and safe among people with active cancer and cancer survivors (13) . As in patients without cancer, the only absolute contraindication for receiving a COVID-19 vaccine is a history of allergic reactions to vaccine components. Adults with COVID-19 and solid tumors seem to have an adequate immune response post-infection, though it may be hindered in patients with hematologic tumors (14) . Additionally, although antineoplastic therapy may blunt lymphocyte proliferation, suppression is not complete, and immune responses can be elicited even while receiving cytotoxic therapy (13) . However, the SOAP-vaccine trial, which measured the immune response following administration of the Pfizer-BioNTech vaccine in adults with cancer, showed that 95% of study participants developed antibodies against SARS-CoV-2 after two vaccine doses, although response was low following one dose (38% of participants with solid tumors and 18% of participants with hematological malignancies developed anti-SARS-CoV-2 antibodies, compared with 94% of participants without known malignancies). This highlights the importance of a timely administration of both vaccine doses for individuals receiving mRNA vaccines, particularly adults with cancer (15) . Results from the VOICE trial are pending, which will prospectively evaluate safety and efficacy of COVID-19 vaccination in 627 adults with cancer undergoing cytotoxic chemotherapy, immunotherapy, and combination schemes (16) . Although targeted therapies and immunotherapy may inhibit antigen presenting functions, T-cell activation, and B-cell signaling, data from previous studies with other types of vaccines shows that patients treated with these medications still generate protective responses (13) . Considering the absence of robust data, the Mexican Society of Oncology (SMEO) formed a multidisciplinary group to draft recommendations regarding COVID-19 vaccination in adults with cancer. These recommendations are based on the best available evidence and a thorough revision of guidelines released by other international societies (17) (18) (19) . Figure 1 ) (21, 22) . This policy prioritizes vaccination of older adults, which represents the most practical approach to immunize the population most at risk for serious and fatal outcomes, given that the prevalence of high-risk comorbidities in older adults reaches 66% (23) . Adults <60 years of age with comorbidities, including cancer, will be next in priority (21) . The complete recommendations are shown in Table 1 . Through these recommendations, SMEO joins the international effort to prioritize patients who are at risk of worse outcomes from COVID-19. We believe these recommendations can be useful not only for oncologists and other physicians practicing in Mexico but also in countries across Latin America with similar issues regarding access to vaccines. It is in the best interest of our societies to achieve the primary goal of reducing severe and fatal cases through the prioritization of vulnerable populations, including patients with cancer, who require the highest protection against this devastating disease. x-x Running title: COVID vaccine guidance for oncologic patients in Mexico COVID-19 México, Información General Severe Covid-19 Effects of cancer on patients with COVID-19: a systematic review and meta-analysis of 63,019 participants Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study Factors associated with COVID-19-related death using OpenSAFELY Comprehensive evaluation of the impact of sociodemographic inequalities on adverse outcomes and excess mortality during the COVID-19 pandemic in Mexico City Strong Social Distancing Measures In The United States Reduced The COVID-19 Growth Rate Effect of the social distancing measures on the spread of COVID-19 in 10 highly infected countries Status of COVID-19 Vaccines within WHO EUL/PQ evaluation process Data. Coronavirus (COVID-19) Vaccinations. Available online at Safety and Efficacy of the BNT162b2 mRNA Covid-19 COVID-19 vaccines for patients with cancer: benefits likely outweigh risks Acute Immune Signatures and Their Legacies in Severe Acute Respiratory Syndrome Coronavirus-2 Infected Cancer Patients Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study COVID-19 vaccination: the VOICE for patients with cancer The ESMO Call to Action on COVID-19 vaccinations and patients with cancer: Vaccinate. Monitor. Educate The SIOG COVID-19 working group recommendations on the rollout of COVID-19 vaccines among older adults with cancer Available online at Política Nacional de Vacunación contra el virus SARS-CoV-2, para la prevención de la COVID-19 en México Priorización inicial y consecutiva para la vacunación contra SARS-CoV-2 en la población mexicana. Recomendaciones preliminares Global, regional, and national estimates of the population at increased risk of severe COVID-19 due to underlying health conditions in 2020: a modelling study Priority COVID-19 Vaccination for Patients with Cancer while Vaccine Supply Is Limited Safety of Influenza Vaccine in Patients With Cancer Receiving Pembrolizumab COVID-19, the Future Vaccine and What It Means for Cancer Patients on Short-term safety of the BNT162b2 mRNA COVID-19 vaccine in patients with cancer treated with immune checkpoint inhibitors Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective Recommendations for COVID-19 vaccination in patients with hematologic cancer ASH-ASTCT COVID-19 Vaccination for HCT and CAR T Cell Recipients: Frequently Asked Questions COVID-19 and Vaccines for the Immunocompromised: Frequently Asked Questions Vaccination for Cancer Patients Receiving Radiation Therapy COVID Vaccination in Cancer Patients: What Vaccination Priority Strategies Should There Be? Why Invest in Communication for Immunization: Evidence and Lessons Learned. A joint publication of the Health Communication Partnership based at Johns Hopkins Bloomberg School of Public Health/Center for Communication Programs (Baltimore) and the United